Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges

Biochem Pharmacol. 2023 Sep:215:115740. doi: 10.1016/j.bcp.2023.115740. Epub 2023 Aug 9.

Abstract

Liver fibrosis is an excessive production, aberrant deposition, and deficit degradation of extracellular matrix (ECM). Patients with unresolved fibrosis ultimately undergo end-stage liver diseases. To date, the effective and safe strategy to cease fibrosis progression remains an unmet clinical need. Since collagens are the most abundant ECM protein which play an essential role in fibrogenesis, the suitable regulation of collagen homeostasis could be an effective strategy for the treatment of liver fibrosis. Therefore, this review provides a brief overview on the dysregulation of ECM homeostasis, focusing on collagens, in the pathogenesis of liver fibrosis. Most importantly, promising therapeutic mechanisms related to biosynthesis, deposition and extracellular interactions, and degradation of collagens, together with preclinical and clinical antifibrotic evidence of drugs affecting each target are orderly criticized. In addition, challenges for targeting collagen homeostasis in the treatment of liver fibrosis are discussed.

Keywords: Collagen; Extracellular matrix; Liver fibrosis; Therapeutic target.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Collagen* / metabolism
  • Extracellular Matrix / metabolism
  • Fibrosis
  • Homeostasis
  • Humans
  • Liver / metabolism
  • Liver Cirrhosis* / metabolism

Substances

  • Collagen